Literature DB >> 21410610

Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options.

Scott Worswick1, Jonathan Cotliar.   

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous reactions that are medication-induced in most instances. While the clinical manifestations of SJS and TEN are well-defined, the optimal treatment for these disorders is not. Case reports have shown benefit with the use of a variety of agents including tumor necrosis factor-alpha inhibitors and cyclophosphamide, whereas thalidomide was associated with an increased mortality. Plasmapheresis and cyclosporine have also demonstrated efficacy anecdotally, albeit with an even smaller number of cases in the literature. Most of the reporting has focused on the use of systemic corticosteroids and intravenous immunoglobulin (IVIG) for these severe reactions. The majority of studies analyzing the use of IVIG in the treatment of SJS/TEN show a benefit, though more recent series cast doubt upon this conclusion. The results of these studies are summarized in this present review study.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21410610     DOI: 10.1111/j.1529-8019.2011.01396.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  12 in total

1.  Steven Johnson Syndrome: Drug or Bug?

Authors:  Kam Lun Ellis Hon; Cheung Lun Paul Choi
Journal:  Indian J Pediatr       Date:  2016-07-27       Impact factor: 1.967

Review 2.  Severe cutaneous adverse drug reactions.

Authors:  Rajesh Verma; Biju Vasudevan; Vijendran Pragasam
Journal:  Med J Armed Forces India       Date:  2013-03-17

3.  Treatment of severe drug reactions by hemodialysis.

Authors:  Rokea A El-Azhary; Michael Z Wang; Ashley B Wentworth; LaTonya J Hickson
Journal:  Int J Dermatol       Date:  2017-11-22       Impact factor: 2.736

4.  Immunoglobulin injection for the treatment of multiple oral ulcers in Stevens-Johnson syndrome.

Authors:  M Cicciù; F Chiera; R Gallizzi; A Cicciù; C D Salpietro
Journal:  Eur Arch Paediatr Dent       Date:  2013-10-01

5.  Toxic epidermal necrolysis due to therapy with cyclophosphamide and mesna. A case report of a patient with seronegative rheumatoid arthritis and rheumatoid vasculitis.

Authors:  A C Chowdhury; D P Misra; P S Patro; V Agarwal
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

6.  Evaluation of the antiapoptotic and anti-inflammatory properties of chitosan in methotrexate-induced oral mucositis in rats.

Authors:  Kani Bilginaylar; Asli Aykac; Serkan Sayiner; Hanife Özkayalar; Ahmet Özer Şehirli
Journal:  Mol Biol Rep       Date:  2022-01-21       Impact factor: 2.316

7.  The effects of systemic cyclosporine in acute Stevens-Johnson syndrome/toxic epidermal necrolysis on ocular disease.

Authors:  Leangelo N Hall; Swapna S Shanbhag; Ramy Rashad; James Chodosh; Hajirah N Saeed
Journal:  Ocul Surf       Date:  2020-05-20       Impact factor: 5.033

Review 8.  Toxic epidermal necrolysis in a child with lupus-associated pancreatitis.

Authors:  Stevic Marija; Budic Ivana; Ristic Nina; Nenadic Dragan; Bokun Zlatko; Jovanovic Branislav; Pejanovic Jelena; Simic Dusica
Journal:  Rheumatol Int       Date:  2017-02-26       Impact factor: 3.580

Review 9.  Drug-related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review.

Authors:  Rohini Arora; Rajesh K Pande; Shikha Panwar; Vivek Gupta
Journal:  Indian J Crit Care Med       Date:  2021-05

Review 10.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.